US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
イギリス
LSE
Selvita Sa (0RKT)
Selvita Sa (0RKT) ニュース

0RKT

Selvita (0RKT)

Selvita Sa

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0RKT

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/06	18 : 40	UK Regulatory	Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting	LSE:0RKT	Selvita Sa
2024/02/15	03 : 12	UK Regulatory	Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS	LSE:0RKT	Selvita Sa
2023/11/03	00 : 02	PR Newswire (US)	Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting	LSE:0RKT	Selvita Sa
2022/09/29	02 : 17	PR Newswire (US)	Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update	LSE:0RKT	Selvita Sa
2022/06/10	18 : 54	PR Newswire (US)	Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress	LSE:0RKT	Selvita Sa
2022/03/09	06 : 50	PR Newswire (US)	Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting	LSE:0RKT	Selvita Sa
2021/06/11	17 : 30	PR Newswire (US)	Ryvu Therapeutics Presents Positive Phase I Data for RVU120 at the Virtual 26th Annual Congress of the European Hematology As...	LSE:0RKT	Selvita Sa
2021/05/28	21 : 08	PR Newswire (US)	Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metas...	LSE:0RKT	Selvita Sa
2021/01/05	06 : 05	PR Newswire (US)	Selvita completes acquisition of Fidelta from Galapagos	LSE:0RKT	Selvita Sa
2020/12/01	21 : 10	PR Newswire (US)	Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be publish...	LSE:0RKT	Selvita Sa
2020/09/10	19 : 51	PR Newswire (US)	Selvita reports strong financial results for H1 2020 and a record backlog	LSE:0RKT	Selvita Sa
2020/06/11	01 : 58	PR Newswire (US)	Ryvu Therapeutics Reports First Quarter 2020 Financial Results	LSE:0RKT	Selvita Sa
2020/06/02	23 : 20	PR Newswire (US)	Ryvu Therapeutics Has Completed the Construction of the R&D Center for Innovative Drugs	LSE:0RKT	Selvita Sa
2020/05/26	15 : 24	PR Newswire (US)	Selvita Reports Financial Results for Q1 2020: Dynamic Increase in Backlog for 2020 and Strong Position on the Market	LSE:0RKT	Selvita Sa
2020/05/14	22 : 30	PR Newswire (US)	Ryvu Therapeutics Announces Availability of Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Pres...	LSE:0RKT	Selvita Sa
2020/04/27	16 : 33	PR Newswire (US)	Selvita and Ardigen Will Receive Funding for the Development of an AI-based High-content Screening Platform	LSE:0RKT	Selvita Sa
2020/04/16	15 : 12	PR Newswire (US)	Galapagos and Ryvu Announce Research Collaboration	LSE:0RKT	Selvita Sa
2020/02/27	20 : 00	PR Newswire (US)	Ryvu Therapeutics to Present Recent Data From Multiple Oncology Programs at AACR 2020 Annual Meeting	LSE:0RKT	Selvita Sa
2019/11/07	20 : 30	PR Newswire (US)	Selvita Q3 2019 Results: Accelerated Growth, 45 Percent Increase in Commercial Revenues and Strong Long-term Outlook	LSE:0RKT	Selvita Sa
2019/11/07	01 : 39	PR Newswire (US)	Ryvu Therapeutics Announces Presentations on CDK8 Inhibitor SEL120 at the 61st ASH Annual Meeting	LSE:0RKT	Selvita Sa
2019/11/06	22 : 00	PR Newswire (US)	Ryvu Therapeutics Reports Third Quarter 2019 Financial Results	LSE:0RKT	Selvita Sa
2019/10/01	23 : 00	PR Newswire (US)	Ryvu Therapeutics and Selvita Announce Registration of Corporate Split by the National Court Register of Poland	LSE:0RKT	Selvita Sa
2019/09/06	15 : 00	PR Newswire (US)	Selvita Announces First Patient Dosed in Phase 1b Study of CDK8 Inhibitor SEL120 in the Treatment of Acute Myeloid Leukemia o...	LSE:0RKT	Selvita Sa
2019/09/05	15 : 00	PR Newswire (US)	Selvita Reports Second Quarter and Half-year 2019 Financial Results	LSE:0RKT	Selvita Sa
2019/09/04	02 : 00	PR Newswire (US)	Polish Financial Supervision Authority Approves Selvita CRO Prospectus, Allowing Corporate Split Into Two Separately Listed C...	LSE:0RKT	Selvita Sa
2019/09/03	18 : 00	PR Newswire (US)	Selvita to Present at Upcoming Conferences in September	LSE:0RKT	Selvita Sa
2019/07/25	15 : 00	PR Newswire (US)	Selvita Appoints Setareh Shamsili, M.D., Ph.D., as Chief Medical Officer	LSE:0RKT	Selvita Sa
2019/05/22	14 : 30	PR Newswire (US)	Selvita Reports First Quarter 2019 Financial Results and Provides Corporate Update	LSE:0RKT	Selvita Sa
2019/05/13	20 : 00	PR Newswire (US)	Selvita to Present at the UBS 2019 Global Healthcare Conference in New York	LSE:0RKT	Selvita Sa
2019/03/28	20 : 43	PR Newswire (US)	Selvita to Separate Oncology Therapeutics and Contract Research Business Units Into Two Global Companies	LSE:0RKT	Selvita Sa

Showing the most relevant articles for your search:LSE:0RKT

WisdomTree Short JPY Lon...

American Financial

Vanguard Mega Cap Growth...

Invesco Real Estate S&P ...

Morgan Stanley Finance L...

K2 Asset Management

NLBNPIT21CY5 20240920 29...

SPDR S&P Pharmaceuticals

West Fraser Timber

Fidelity Sustainable Tar...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約